144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial

This study investigates the long-term efficacy and safety of bulevirtide monotherapy for chronic hepatitis D (CHD) over 144 weeks, including outcomes after treatment discontinuation. The results indicate that while response rates decreased post-treatment, a subset of patients maintained undetectable hepatitis D virus (HDV) RNA, with the duration of undetectability at the end of treatment being a key predictor of sustained response. The findings suggest that while most patients benefit from continued treatment, some may safely discontinue without losing their therapeutic gains.